These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1152 related items for PubMed ID: 18673365

  • 21. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B.
    BMJ; 2010 Feb 02; 340():c147. PubMed ID: 20124563
    [Abstract] [Full Text] [Related]

  • 22. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
    Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A.
    J Drugs Dermatol; 2010 Aug 02; 9(8):928-37. PubMed ID: 20684143
    [Abstract] [Full Text] [Related]

  • 23. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 02; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 24. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.
    Br J Dermatol; 2006 Oct 02; 155(4):808-14. PubMed ID: 16965432
    [Abstract] [Full Text] [Related]

  • 25. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
    Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR, Unite Study Group.
    J Drugs Dermatol; 2008 Mar 02; 7(3):245-53. PubMed ID: 18380206
    [Abstract] [Full Text] [Related]

  • 26. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S.
    Br J Dermatol; 2006 Jul 02; 155(1):156-9. PubMed ID: 16792768
    [Abstract] [Full Text] [Related]

  • 27. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb 02; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Feb 02; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE.
    Arthritis Rheum; 2008 Jul 02; 58(7):1921-30. PubMed ID: 18576334
    [Abstract] [Full Text] [Related]

  • 30. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA.
    Int J Immunopathol Pharmacol; 2006 Jul 02; 19(1):225-9. PubMed ID: 16569361
    [Abstract] [Full Text] [Related]

  • 31. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 02; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 32. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR.
    Arthritis Rheum; 2004 Jul 02; 50(7):2240-5. PubMed ID: 15248223
    [Abstract] [Full Text] [Related]

  • 33. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators.
    Lancet; 2015 Aug 08; 386(9993):552-61. PubMed ID: 26051365
    [Abstract] [Full Text] [Related]

  • 34. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 08; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
    Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C.
    Br J Clin Pharmacol; 2006 Oct 08; 62(4):435-45. PubMed ID: 16995864
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
    Br J Dermatol; 2011 Nov 08; 165(5):1109-17. PubMed ID: 21910713
    [Abstract] [Full Text] [Related]

  • 37. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec 08; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 38. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 08; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 39. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
    Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Toole J, Vieira A, Poulin-Costello M.
    J Eur Acad Dermatol Venereol; 2015 Feb 08; 29(2):361-366. PubMed ID: 24980988
    [Abstract] [Full Text] [Related]

  • 40. Puerto Rico psoriasis study group: efficacy and safety of etanercept.
    González-Chavez JR, Berlingeri-Ramos AC, Sánchez Casiano MA.
    J Drugs Dermatol; 2005 Feb 08; 4(6):735-9. PubMed ID: 16302559
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.